References
- Malin GL, Morris RK, Khan KS. Strength of association between umbilical cord pH and perinatal and long term outcomes: systematic review and meta-analysis. BMJ. 2010;340:c1471.
- Van de Riet JE, Vandenbussche FP, Le Cessie S, et al. Newborn assessment and long-term adverse outcome: a systematic review. Am J Obstet Gynecol. 1999;180:1024–1029.
- Shennan AH, Smith R, Browne D, et al. The elective use of oxytocin infusion during labour in nulliparous women using epidural analgesia: a randomised double-blind placebo-controlled trial. Int J Obstet Anesth. 1995;4:78–81.
- Cluett ER, Pickering RM, Getliffe K, et al. Randomised controlled trial of labouring in water compared with standard of augmentation for management of dystocia in first stage of labour. BMJ. 2004;328:314.
- Hansen SL, Clark SL, Foster JC. Active pushing versus passive fetal descent in the second stage of labor: a randomized controlled trial. Obstet Gynecol. 2002;99:29–34.
- Goldaber KG, Gilstrap LC 3rd, Leveno KJ, et al. Pathologic fetal acidemia. Obstet Gynecol. 1991;78:1103–1107.
- Ross MG, Gala R. Use of umbilical artery base excess: algorithm for the timing of hypoxic injury. Am J Obstet Gynecol. 2002;187:1–9.
- Hasegawa J, Ikeda T, Toyokawa S, et al. Prevention Recurrence Committee. Relevant obstetric factors associated with fetal heart rate monitoring for cerebral palsy in pregnant women with hypertensive disorder of pregnancy. J Obstet Gynaecol Res. 2018;44:647–654.
- Ananth CV, Peltier MR, Chavez MR, et al. Recurrence of ischemic placental disease. Obstet Gynecol. 2007;110:128–133.
- Ananth CV, Vintzileos AM. Maternal-fetal conditions necessitating a medical intervention resulting in preterm birth. Am J Obstet Gynecol. 2006;195:1557–1563.
- Anceschi MM, Piazze JJ, Maranghi L, et al. Maternal serum uric acid as predictor of fetal acidemia. Int J Gynecol Obstet. 2002;77:35–36.
- Cheng SB, Sharma S. Preeclampsia and health risks later in life: an immunological link. Semin Immunopathol. 2016;38:699–708.
- Zhu C, Anderson AC, Schubart A, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6:1245–1252.
- Wang SC, Zhu X, Xu YY, et al. Programmed cell death-1 (PD-1) and T-cell immunoglobulin mucin-3 (Tim-3) regulate CD4+ T cells to induce Type 2 helper T cell (Th2) bias at the maternal-fetal interface. Hum Reprod. 2016;31:700–711.
- Kanninen TT, de Andrade Ramos BR, Jaffe S, et al. Inhibition of autophagy by sera from pregnant women. Reprod Sci. 2013;20:1327–1331.
- Liao J, Zhang Q, Liao Y, et al. Association of T-cell immunoglobulin and mucin domain-containing molecule 3 (Tim-3) polymorphisms with susceptibility and disease progression of HBV infection. PLoS One. 2014;9:e98280.
- Lanteri MC, Diamond MS, Law JP, et al. Increased frequency of Tim-3 expressing T cells is associated with symptomatic West Nile virus infection. PLoS One. 2014;9:e92134.
- Lu X, McCoy KS, Xu J, et al. Galectin-9 ameliorates respiratory syncytial virus-induced pulmonary immunopathology through regulating the balance between Th17 and regulatory T cells. Virus Res. 2015;195:162–171.
- Hao H, He M, Li J, et al. Upregulation of the Tim-3/Gal-9 pathway and correlation with the development of preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2015;194:85–91.
- Kanzaki M, Wada J, Sugiyama K, et al. Galectin-9 and T cell immunoglobulin mucin-3 pathway is a therapeutic target for type 1 diabetes. Endocrinology. 2012;153:612–620.
- Anderson AC, Anderson DE. TIM-3 in autoimmunity. Curr Opin Immunol. 2006;18:665–669.
- Vargas-Rojas MI, Solleiro-Villavicencio H, Soto-Vega E. Th1, Th2, Th17 and Treg levels in umbilical cord blood in preeclampsia. J Matern Fetal Neonatal Med. 2016;29:1642–1645.
- Pearce BD, Nguyen PH, Gonzalez-Casanova I, et al. Pre-pregnancy maternal plasma cytokine levels and risks of small-for-gestational-age at birth. J Matern Fetal Neonatal Med. 2016;29:4065–4069.